By Andrew Silver SHANGHAI (Reuters) -Drug research and development firms in China including WuXi AppTec and WuXi Biologics ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

SINGAPORE—China is racing toward economic self-sufficiency by weaning itself off American technology. But it has made a ...

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech ...

China's biotechnology stocks have experienced a significant rally, outperforming AI, with a 60% surge since January due to ...

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

China's biotechnology sector is experiencing notable growth, with the ChinaAMC Hang Seng Biotech ETF, tracking the Hang Seng ...

Pfizer ( PFE -1.29%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...